Alpha9 Theranostics
Alpha9 Theranostics
Developing novel radiopharmaceuticals for targeted cancer treatment using advanced molecular imaging and therapy.
About
Technology stack
detected 2026-05-22No comments yet. Be the first to share your take.
What does Alpha9 Theranostics do?
Alpha9 Theranostics is a biotechnology company focused on the development of next-generation radiopharmaceuticals for the diagnosis and treatment of cancer. They leverage their expertise in molecular imaging and targeted delivery to create innovative theranostic agents that can precisely identify and eliminate cancer cells.
How much funding has Alpha9 Theranostics raised?
Alpha9 Theranostics has raised a total of $10M in funding. The most recent round on record is Seed.
Where is Alpha9 Theranostics headquartered?
Alpha9 Theranostics is headquartered in Vancouver, Canada.
When was Alpha9 Theranostics founded?
Alpha9 Theranostics was founded in 2017.
What industry does Alpha9 Theranostics operate in?
Alpha9 Theranostics operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Radiopharmaceuticals.
What is Alpha9 Theranostics's current status?
Alpha9 Theranostics's current operating status is: Inactive.
What is Alpha9 Theranostics's revenue?
StartupHub estimates Alpha9 Theranostics's annual revenue at $1.5M (range $328K to $4.6M, 32% confidence), based on comparable companies in the sector.
What is Alpha9 Theranostics's valuation?
StartupHub estimates Alpha9 Theranostics's effective valuation at $38.8M (range $25.0M to $60.0M, 10% confidence), based on comparable companies in the sector.